Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Gastrointestinal stromal tumor (GIST)
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-15 of 15 for your search:
Start Over
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB04030, NCT00812240
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201404101, NCT01790035
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13-162, NCT01991379
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALDOXORUBICIN-P1/2-STS-03, NCT02235701
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-140, NCT02257541
A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PLX121-01, NCT02401815
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181196, 2011-002008-33, NCT01396148
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 and over
Sponsor: NCI
Protocol IDs: 130208, 13-C-0208, NCT02015065
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-09138, NCI-2011-00920, NCT01376505
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GC0212, NCT01640665
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01165, CDR0000737378, 12-083, 9172, P30CA008748, U01CA069856, NCT01643278
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: 2012-0784, NCI-2013-00030, NCT01738139
Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: POLARIS2013-001, NCT02102022
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-149, NCT02164240
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140150, 14-C-0150, NCT02192541
Start Over